Cargando…

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer

In this study we investigated the use of cancer cell protein expression of ABCG2 to predict efficacy of systemic first-line irinotecan containing therapy in patients with metastatic colorectal cancer (mCRC). From a Danish national cohort, we identified 119 mCRC patients treated with irinotecan conta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palshof, Jesper Andreas, Cederbye, Camilla Natasha, Høgdall, Estrid Vilma Solyom, Poulsen, Tim Svenstrup, Linnemann, Dorte, Nygaard, Sune Boris, Stenvang, Jan, Christensen, Ib Jarle, Jensen, Benny Vittrup, Pfeiffer, Per, Brünner, Nils, Yilmaz, Mette, Viuff, Birgitte Martine, Nielsen, Dorte Lisbet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404184/ https://www.ncbi.nlm.nih.gov/pubmed/32708825 http://dx.doi.org/10.3390/ijms21145027

Ejemplares similares

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2017)

Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue
por: Cederbye, Camilla Natasha, et al.
Publicado: (2016)

MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability
por: Boisen, Mogens Karsbøl, et al.
Publicado: (2015)

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab
por: Skougaard, Kristin, et al.
Publicado: (2014)

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
por: Kümler, Iben, et al.
Publicado: (2019)

Measuring KRAS Mutations in Circulating Tumor DNA by Droplet Digital PCR and Next-Generation Sequencing
por: Demuth, Christina, et al.
Publicado: (2018)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

Mucosal expression of PI3, ANXA1, and VDR discriminates Crohn’s disease from ulcerative colitis
por: James, Jaslin Pallikkunnath, et al.
Publicado: (2023)

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
por: Kümler, Iben, et al.
Publicado: (2015)

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics
por: Kümler, I., et al.
Publicado: (2018)

miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3(rd) Line Cetuximab and Irinotecan
por: Schou, Jakob V., et al.
Publicado: (2014)

Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2018)

Systematic review: brain metastases from colorectal cancer—Incidence and patient characteristics
por: Christensen, Troels Dreier, et al.
Publicado: (2016)

MicroRNA characteristics in epithelial ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2021)

Potential Targeted Therapies in Ovarian Cancer
por: Sisman, Yagmur, et al.
Publicado: (2022)

Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer
por: Gilbert, Duncan C, et al.
Publicado: (2016)

Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (Trop-2) and precision treatment of breast cancer
por: Stenvang, Jan, et al.
Publicado: (2022)

Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour
por: Brinch, Charlotte, et al.
Publicado: (2021)

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022)

Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass
por: Oliveira, Douglas Nogueira Perez, et al.
Publicado: (2019)

Pre- and Perioperative Inflammatory Biomarkers in Older Patients Resected for Localized Colorectal Cancer: Associations with Complications and Prognosis
por: Dolin, Troels Gammeltoft, et al.
Publicado: (2021)

Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development
por: Stenvang, Jan, et al.
Publicado: (2013)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Use of asthma drugs and prevalence of molar incisor hypomineralization
por: Wogelius, Pia, et al.
Publicado: (2020)

DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis
por: Plougmann, Julie Isabelle, et al.
Publicado: (2019)

The influence of insulin-related genetic variants on fetal growth, fetal blood flow, and placental weight in a prospective pregnancy cohort
por: Reim, Pauline K., et al.
Publicado: (2023)

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
por: Kalanxhi, Erta, et al.
Publicado: (2018)

An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial
por: Stenvang, Jan, et al.
Publicado: (2020)

Gene expression profile association with poor prognosis in epithelial ovarian cancer patients
por: Oliveira, Douglas V. N. P., et al.
Publicado: (2021)

Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases
por: Oliveira, Douglas V. N. P., et al.
Publicado: (2020)

Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus
por: Vestergaard, Lau K., et al.
Publicado: (2021)

FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance
por: Westover, David, et al.
Publicado: (2015)

Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
por: Boisen, Mogens K., et al.
Publicado: (2014)

The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer
por: Lin, Xue, et al.
Publicado: (2015)

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2017)

The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP
por: Ambjørner, Sophie E. B., et al.
Publicado: (2020)

MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts
por: Honorat, Mylène, et al.
Publicado: (2015)

Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
por: Sisman, Yagmur, et al.
Publicado: (2022)

Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals
por: Thorsen, Stine Buch, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7985en8oimc7ha7me0d6o61ilv